Insmed reported $18.84M in Interest Expense on Debt for its fiscal quarter ending in June of 2026.





Interest Expense On Debt Change Date
BioMarin Pharmaceutical USD 63.29M 48.34M Jun/2026
Cytokinetics USD 34.83M 1.5M Jun/2026
DBV Technologies USD 461K 323.71K Mar/2025
Gilead Sciences USD 247M 7M Jun/2026
Heron Therapeutics USD 600K 100K Dec/2024
Insmed USD 18.84M 1.24M Jun/2026
Novartis USD 281M 8M Sep/2025
Regeneron Pharmaceuticals USD 11M 1.9M Jun/2026
Sarepta Therapeutics USD 21.51M 205K Jun/2026
Ultragenyx Pharmaceutical USD 22M 1000K Jun/2026
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025